Anthracycline-induced cardiotoxicity is a complex, multifactorial process involving oxidative stress, topoisomerase IIβ inhibition, mitochondrial dysfunction, and disrupted iron and calcium homeostasis.
Anthracycline-induced cardiotoxicity remains a significant clinical challenge, emphasizing the need for better molecular characterization and genetic profiling to identify high-risk patients.
Anthracyclines (ANTs) are powerful drugs that have reduced the mortality of cancer patients. However, their use is limited by the development of cardiotoxicity (CTX), which is dose dependent and may lead to left ventricular dysfunction and heart failure. Although various strategies have been suggested to reduce the negative effects of ANTs, CTX is still an important unresolved clinical issue. This may be due at least partly to the incomplete characterization of the molecular and cellular mechanisms of ANT-induced CTX. In addition, although various forms of cardiac damage have been demonstrated with the use of these drugs in experimental studies, it is not yet clear how these translate to the clinical setting. Appropriate characterization of potential candidates for ANT-based therapies is essential to decide whether to administer these drugs. Hopefully, new information from genetic profiling will help to identify patients who are at high risk of developing CTX.
Mele et al. (Sun,) conducted a review in Anthracycline-induced cardiotoxicity. Anthracyclines was evaluated. Anthracycline-induced cardiotoxicity is a complex, multifactorial process involving oxidative stress, topoisomerase IIβ inhibition, mitochondrial dysfunction, and disrupted iron and calcium homeostasis.